DaVitaNYSE: DVA

Even though DaVita Inc. has been successful and has the potential to grow, I consider it a "Hold" because of its high debt, absence of dividends, and current overvaluation. The company is strong in dialysis services, but it faces major risks from debt payments, economic conditions, and possible changes in policies. Recent financial results show a drop in net income and rising debt costs, which supports my cautious view on its value.

Over 8,300 people took part in the annual Move It With Purpose (MIWP) event to support Bridge of Life. This successful event, organized by DaVita, included participants from the kidney care community, as well as friends and family. The month-long initiative promotes various physical activities like walking, running, and cycling to help prevent and treat chronic diseases worldwide.

DENVER, Nov. 8, 2024 /PRNewswire/ -- DaVita Inc. (NYSE: DVA) has announced that its CFO, Joel Ackerman, and group VP of investor relations, Nic Eliason, will take part in a discussion with investors at the UBS Global Healthcare Conference 2024 on Tuesday, November 12, 2024, at 12:30 pm PST (3:30 pm EST). You can watch the live webcast by visiting the UBS website and registering for free.

DVA's strong revenue from dialysis patient services boosts its performance in the third quarter.

DaVita HealthCare (DVA) reported quarterly earnings of $2.59 per share, which is lower than the Zacks Consensus Estimate of $2.76 per share. This is also a decrease from the earnings of $2.85 per share from the same period last year.

On Tuesday, DaVita announced that its profits for the third quarter fell short of Wall Street's expectations due to increased costs for patient care.

DENVER, Oct. 29, 2024 /PRNewswire/ -- DaVita Inc. (NYSE: DVA) shared its financial and operational results for the quarter that ended on September 30, 2024. Javier Rodriguez, the CEO of DaVita Inc., stated, "We are committed to offering high-quality care to our patients while achieving strong financial results in the third quarter." He also expressed appreciation for the incredible strength shown by both patients and frontline caregivers during the recent severe storms.

The enhancement in RPT probably helped increase DaVita's revenue in the third quarter.

DENVER and SAN DIEGO, Oct. 23, 2024 /PRNewswire/ -- DaVita Clinical Research (DCR), a top company in kidney care research and a part of DaVita Inc., will share findings from five new research projects at the American Society of Nephrology (ASN)'s annual Kidney Week event happening now in San Diego, CA. DCR aims to enhance racial equity in organ transplants and improve important clinical quality indicators like hospitalizations, addressing critical challenges in nephrology that impact various communities.